Gyre Therapeutics, Inc. (GYRE) AI Stock Analysis

Gyre Therapeutics, Inc. specializes in developing small-molecule therapies targeting organ fibrosis, anti-inflammatory, and anti-fibrotic conditions. Its commercial product, ETUARY (Pirfenidone), is approved for idiopathic pulmonary fibrosis and is in Phase 3 clinical trials for dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company's pipeline includes F351 (Hydronidone), undergoing Phase 3 evaluation for chronic hepatitis B liver fibrosis and Phase 1 trials for liver fibrosis related to nonalcoholic steatohepatitis. Gyre is also advancing F573 in Phase 2 for acute/acute-on-chronic liver failure, alongside preclinical candidates F528 and F230. Headquartered in San Diego, California, Gyre operates as a subsidiary of GNI USA, Inc.

Gyre's revenue grew from $7.3M in FY2021 to $116.6M in FY2025, reflecting a 5-year revenue CAGR of 41.0%. In FY2025, revenue increased 10.2% year-over-year, delivering a gross margin of 95.4%, an operating margin of 9.9%, and net income of $5.0M. For the trailing twelve months ending June 30, 2026, revenue stood at $109.8M with a net loss reflected in a profit margin of -19.3% and EPS of -$0.25. In the latest quarter ending June 30, 2026, quarterly revenue fell 2.1% year-over-year, while quarterly earnings grew 166.2%.

As of June 30, 2026, Gyre held $74.8M in cash and short-term investments against $3.4M in total debt, leaving net cash at $71.4M. Its current ratio stood at 4.26, and its debt-to-equity ratio was 0.03 based on shareholders' equity of $130.4M. In FY2025, operating cash flow was $1.0M, free cash flow was -$180,000, and capital expenditures were $1.2M. Share count increased 220.3% over five years.

Gyre trades at a forward P/E of 188.7x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales ratio is 5.9x versus the peer median of 4.1x, and its EV-to-EBITDA multiple is 131.0x compared to the peer median of 12.0x. Over the past year, Gyre shares declined 30.4%, while the S&P 500 (SPY) gained 16.8%. Over five years, the stock is down 83.6% compared to an 83.0% gain for the benchmark.

Wall Street coverage includes 3 Strong Buy ratings and 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target of $18.67 represents a 207.0% premium over the last close of $6.08. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.40 and revenue of $109.5M. For the following fiscal year, 2 analysts expect revenue of $139.6M and EPS of -$0.23. The company beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 6, 2026.

This page is an AI-written research summary of Gyre Therapeutics, Inc. (GYRE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GYRE income statement, GYRE balance sheet, GYRE key metrics, GYRE analyst forecast, GYRE chart. See the GYRE stock overview for the latest quote and news.